Ozempic’s Success Is Bad News for Rivals

Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily." Hosted by Carol Massar and Tim StenovecHear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius ...  Show more

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Kevin Warsh waited almost a decade before finally clinching President Donald Trump’s nomination to be chair of the Federal Reserve. He won’t need to ...  Show more

Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

As a number of existing therapies are being re-purposed to help patients with the most severe Covid-19 symptoms, we speak to a UK-based bioscience company about a drug they've developed and explore how it is being used in Italy. 

Guests: </stro ...

In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry.

How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 1 ...